Results 161 to 170 of about 260,092 (192)

Policy analysis: Key milestones in MDR-TB management over the past decade in South Africa. [PDF]

J Public Health Afr
Davids LC, Crowley T.
europepmc   +1 more source

Off-label evaluation of the BD MAX MDR-TB assay for rapid diagnosis of rifampicin and isoniazid resistance of <i>Mycobacterium tuberculosis</i> clinical isolates in a high-volume reference laboratory. [PDF]

J Clin Microbiol
Brandao AP, Ferreira FMdA, Simeao FCdS, Ferrazoli L, Chimara E, de Oliveira RS, Pinhata JMW.   +6 more
europepmc   +1 more source

Characterizing Musculoskeletal and Neurological Toxicities Associated With the BPaLM Regimen: A Clinical Evaluation of Arthralgia and Peripheral Neuropathy in Patients With Multidrug-Resistant Tuberculosis (MDR-TB). [PDF]

Cureus
Khan Z, Ali G, Rumman, Ashraf, Naveed A, Salam S, Ullah U, Ismail A, Altaf A.   +8 more
europepmc   +1 more source

Stigma and health-related quality of life (HRQoL) among people with multidrug-resistant tuberculosis (MDR-TB): A cross-sectional study in Indonesia. [PDF]

Narra J
Arifin B, Sarwadan MG, Wahyudin E, Sarifah LM, Fuady A, Purba FD, Alkaff SD, Ardiansyah A, Madolangan J.   +8 more
europepmc   +1 more source

The Association of Chronic Pulmonary Aspergillosis and Chronic Pulmonary Histoplasmosis with MDR-TB Patients in Indonesia. [PDF]

J Fungi (Basel)
Soeroso NN, Siahaan L, Khairunnisa S, Anggriani RAH, Aida A, Eyanoer PC, Daulay ER, Burhan E, Rozaliyani A, Ronny R, Adawiyah R, Denning DW, Wahyuningsih R.   +12 more
europepmc   +1 more source

Exploring HIV disease indicators at MDR-TB treatment initiation in South Africa. [PDF]

Int J Tuberc Lung Dis
Geiger K, Patil A, Bergman A, Budhathoki C, Heidari O, Lowensen K, Mthimkhulu N, McNabb KC, Mmed NN, Ngozo J, Reynolds N, Farley JE.   +11 more
europepmc   +1 more source

Diagnostic Accuracy of BD MAX MDR-TB Assay Performed on Bronchoscopy Specimens in Patients with Suspected Pulmonary Tuberculosis. [PDF]

Tuberc Respir Dis (Seoul)
Ko SJ, Yoon KH.
europepmc   +1 more source

Performance evaluation of alternative bacteriological measures of response to MDR-TB therapy during the initial 16 weeks of treatment

Ssengooba W, Musisi E, Semugenze D, Komakech K, Ndema M, Sekaggya CW, Adakun S, Sloan DJ, Katamba A, Lamorde M, Joloba M, Sabiiti W.   +11 more
europepmc   +1 more source